MedTrace Logo

Evaluating the Safety and Efficacy of AD17002 Intranasal Spray in Treating Participants With Mild to Moderate COVID-19

NCT05541510 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2025-09-10

No results posted yet for this study

Summary

AD17002 enhances nasal mucosal innate immunity and has met safety and efficacy endpoints in studies of nasal adjuvants or intranasal immunomodulators. This study aims to evaluate the safety and effectiveness of AD17002 in treating patients with mild to moderate COVID-19.

All participants will be randomly divided into 1:1:1 groups and will receive standard treatment. Additionally, participants will be given either a placebo, 20, or 40 μg of AD17002 via intranasal delivery, and clinical progress will be compared.

Conditions

Interventions

BIOLOGICAL

AD17002 + Formulation buffer

Intranasal innate immune modulator

BIOLOGICAL

Placebo

Formulation buffer

Sponsors & Collaborators

  • Gadjah Mada University

    collaborator OTHER

  • Advagene Biopharma Co. Ltd.

    lead INDUSTRY

Principal Investigators

  • Jarir At Thobari, MD. PhD. · Gadjah Mada University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2024-08-05
Completion
2024-08-25

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05541510 on ClinicalTrials.gov